BACK
GLOBAL EXECUTIVE MOVES

April 2021
Nuvalent, Inc. Appoints Alexander Drilon to Its Scientific Advisory Board
Nuvalent, Inc. appointed Alexander Drilon, M.D., to its Scientific Advisory Board (SAB). Alexander currently serves as Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) and brings deep expertise in early-phase clinical trials for cancer.
Nuvalent, Inc. is based in Cambridge, Massachusetts, and uses precisely targeted therapies for patients with cancer.